Changwei Zhou

Changwei Zhou

Binghamton University - Vestal / United States
Social Sciences / Linguistics and Literature
AD Scientific Index ID: 5680618
State University of New York at Binghamton
person_outline Changwei Zhou's MOST POPULAR ARTICLES
1-) Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-upT Martin, SZ Usmani, JG Berdeja, M Agha, AD Cohen, P Hari, D Avigan, ...Journal of Clinical Oncology 41 (6), 1265-1274, 20233052023
2-) Updated results from CARTITUDE-1: phase 1b/2Study of ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with …T Martin, SZ Usmani, JG Berdeja, A Jakubowiak, M Agha, AD Cohen, ...Blood 138, 549, 2021672021
3-) Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.SZ Usmani, TG Martin, JG Berdeja, AJ Jakubowiak, ME Agha, AD Cohen, ...Journal of Clinical Oncology 40 (16_suppl), 8028-8028, 2022182022
4-) Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysisA Jakubowiak, SZ Usmani, JG Berdeja, M Agha, AD Cohen, P Hari, ...Blood 138, 3938, 2021162021
5-) Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLJ Costa, P Hari, JG Berdeja, V De Stefano, F Gay, B Hooper, M Bartlett, ...Current Medical Research and Opinion 38 (10), 1759-1767, 202262022